Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04968210 · ClinicalTrials.gov registry record
Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)
A clinical trial, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- 3
- Enrollment target
NCT04968210 is a clinical trial that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 3 participants.
The verdict
NCT04968210 has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- 3 participants
- Enrollment target
Study Summary
Pulmonary arterial hypertension (PAH) is a progressive disease in which clinically relevant symptoms present a few years after the onset in rise of pulmonary arterial pressure. Increased PA pressure presents an overload on the right ventricle (RV), with RV failure being a common cause of mortality in PAH. Current therapeutic targets help reduce vascular resistance and RV afterload, however, RV dysfunction may continue to progress. Therefore, the reason for RV failure in PAH cannot be contributed to altered vascular hemodynamics alone but may be related to metabolic alterations and failure of adaptive mechanisms in the RV. Providing a better understanding of metabolic remodeling in RV failure may permit the development of RV-targeted pharmacological agents to maintain RV function despite increased pulmonary vascular pressures. This study will evaluate how cardiac metabolism changes in response to pulmonary vasodilator therapy in patients with pulmonary arterial hypertension.
Interventions
- DRUG Hyperpolarized 13C-pyruvate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2024-12-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04968210
The ClinicalTrials.gov registry entry for NCT04968210 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hyperpolarized 13C-pyruvate is the first listed.
NCT04968210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04968210 about?
NCT04968210 is a clinical study titled "Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)". Pulmonary arterial hypertension (PAH) is a progressive disease in which clinically relevant symptoms present a few years after the onset in rise of pulmonary arterial pressure. Increased PA pressure presents an overload on the right ventricle (RV), with RV failure being a common cause of mortality i...
What is the current status of trial NCT04968210?
This trial is currently completed. The enrollment target is 3 participants. The study started on 2022-05-27. Estimated completion is 2024-12-17.
What interventions are being tested in trial NCT04968210?
The interventions under investigation include: Hyperpolarized 13C-pyruvate (DRUG).
Who is sponsoring clinical trial NCT04968210?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.